Literature DB >> 31461653

MAVS O-GlcNAcylation Is Essential for Host Antiviral Immunity against Lethal RNA Viruses.

Nan Song1, Qi Qi2, Ruiyuan Cao3, Bingjie Qin3, Bo Wang3, Yuxia Wang3, Lei Zhao3, Wei Li3, Xianli Du3, Feng Liu3, Yunzheng Yan3, Wen Yi4, Hailu Jiang3, Tao Li5, Tao Zhou5, Hui-Yan Li5, Qing Xia5, Xue-Min Zhang2, Wu Zhong6, Ai-Ling Li7, Xiaotao Duan8.   

Abstract

It is known that lethal viruses profoundly manipulate host metabolism, but how the metabolism alternation affects the immediate host antiviral immunity remains elusive. Here, we report that the O-GlcNAcylation of mitochondrial antiviral-signaling protein (MAVS), a key mediator of interferon signaling, is a critical regulation to activate the host innate immunity against RNA viruses. We show that O-GlcNAcylation depletion in myeloid cells renders the host more susceptible to virus infection both in vitro and in vivo. Mechanistically, we demonstrate that MAVS O-GlcNAcylation is required for virus-induced MAVS K63-linked ubiquitination, thereby facilitating IRF3 activation and IFNβ production. We further demonstrate that D-glucosamine, a commonly used dietary supplement, effectively protects mice against a range of lethal RNA viruses, including human influenza virus. Our study highlights a critical role of O-GlcNAcylation in regulating host antiviral immunity and validates D-glucosamine as a potential therapeutic for virus infections.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MAVS; O-GlcNAcylation; RNA virus; antiviral immunity; glucosamine; influenza; interferon

Year:  2019        PMID: 31461653     DOI: 10.1016/j.celrep.2019.07.085

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  19 in total

1.  Innate Immune Responses and Pulmonary Diseases.

Authors:  Tao Liu; Siqi Liu; Xiaobo Zhou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Astrocyte Bioenergetics and Major Psychiatric Disorders.

Authors:  Ivan V Maly; Michael J Morales; Mikhail V Pletnikov
Journal:  Adv Neurobiol       Date:  2021

Review 3.  The Role of O-GlcNAcylation in Immune Cell Activation.

Authors:  Amy Qiang; Chad Slawson; Patrick E Fields
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-27       Impact factor: 5.555

Review 4.  O-GlcNAcylation and its role in the immune system.

Authors:  Yi-Hsuan Chang; Chia-Lin Weng; Kuo-I Lin
Journal:  J Biomed Sci       Date:  2020-04-29       Impact factor: 8.410

5.  O-Linked N-Acetylglucosamine Modification of Mitochondrial Antiviral Signaling Protein Regulates Antiviral Signaling by Modulating Its Activity.

Authors:  Junghwa Seo; Yun Soo Park; Tae Hyun Kweon; Jingu Kang; Seongjin Son; Han Byeol Kim; Yu Ri Seo; Min Jueng Kang; Eugene C Yi; Yong-Ho Lee; Jin-Hong Kim; Boyoun Park; Won Ho Yang; Jin Won Cho
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

6.  Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.

Authors:  James J DiNicolantonio; Jorge Barroso-Aranda
Journal:  Med Hypotheses       Date:  2020-07-02       Impact factor: 1.538

7.  Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.

Authors:  Mark F McCarty; James J DiNicolantonio
Journal:  Prog Cardiovasc Dis       Date:  2020-02-12       Impact factor: 8.194

Review 8.  Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity.

Authors:  Johannes Burtscher; Giuseppe Cappellano; Akiko Omori; Takumi Koshiba; Grégoire P Millet
Journal:  iScience       Date:  2020-09-29

Review 9.  Azithromycin and glucosamine may amplify the type 1 interferon response to RNA viruses in a complementary fashion.

Authors:  James J DiNicolantonio; Jorge Barroso-Aranda; Mark F McCarty
Journal:  Immunol Lett       Date:  2020-09-28       Impact factor: 3.685

Review 10.  The role of O-GlcNAcylation in immunity against infections.

Authors:  Marjolein Quik; Cornelis H Hokke; Bart Everts
Journal:  Immunology       Date:  2020-08-26       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.